TY - JOUR
T1 - Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12)
T2 - A randomised, double-blind, placebo-controlled phase 3 trial
AU - Bois, Andreas du
AU - Kristensen, Gunnar
AU - Ray-Coquard, Isabelle
AU - Reuss, Alexander
AU - Pignata, Sandro
AU - Colombo, Nicoletta
AU - Denison, Ursula
AU - Vergote, Ignace
AU - Del Campo, Jose
AU - Ottevanger, P. B.
AU - Heubner, Martin
AU - Minarik, Thomas
AU - Sevin, Emmanuel
AU - De Gregorio, Nikolaus
AU - Bidzinski, Mariusz
AU - Pfisterer, J.
AU - Malander, Susanne
AU - Hilpert, Felix
AU - Mirza, Mansoor Raza
AU - Scambia, Giovanni
AU - Meier, Werner
AU - Nicoletto, Maria Ornella
AU - Bjorge, Line
AU - Lortholary, Alain
AU - Sailer, Martin Oliver
AU - Merger, Michael
AU - Harter, Philipp
N1 - già in RC 2015, inserito anche in SIPS
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. Methods: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose. Patients were randomly assigned (2:1) via an interactive voice or web-based response system to receive six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m2) in addition to either 200 mg of nintedanib (nintedanib group) or placebo (placebo group) twice daily on days 2-21 of every 3-week cycle for up to 120 weeks. Patients, investigators, and independent radiological reviewers were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01015118. Findings: Between Dec 9, 2009, and July 27, 2011, 1503 patients were screened and 1366 randomly assigned by nine study groups in 22 countries: 911 to the nintedanib group and 455 to the placebo group. 486 (53%) of 911 patients in the nintedanib group experienced disease progression or death compared with 266 (58%) of 455 in the placebo group. Median progression-free survival was significantly longer in the nintedanib group than in the placebo group (17·2 months [95% CI 16·6-19·9] vs 16·6 months [13·9-19·1]; hazard ratio 0·84 [95% CI 0·72-0·98]; p=0·024). The most common adverse events were gastrointestinal (diarrhoea: nintedanib group 191 [21%] of 902 grade 3 and three [
AB - Background: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. Methods: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose. Patients were randomly assigned (2:1) via an interactive voice or web-based response system to receive six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m2) in addition to either 200 mg of nintedanib (nintedanib group) or placebo (placebo group) twice daily on days 2-21 of every 3-week cycle for up to 120 weeks. Patients, investigators, and independent radiological reviewers were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01015118. Findings: Between Dec 9, 2009, and July 27, 2011, 1503 patients were screened and 1366 randomly assigned by nine study groups in 22 countries: 911 to the nintedanib group and 455 to the placebo group. 486 (53%) of 911 patients in the nintedanib group experienced disease progression or death compared with 266 (58%) of 455 in the placebo group. Median progression-free survival was significantly longer in the nintedanib group than in the placebo group (17·2 months [95% CI 16·6-19·9] vs 16·6 months [13·9-19·1]; hazard ratio 0·84 [95% CI 0·72-0·98]; p=0·024). The most common adverse events were gastrointestinal (diarrhoea: nintedanib group 191 [21%] of 902 grade 3 and three [
UR - http://www.scopus.com/inward/record.url?scp=84955299214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955299214&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(15)00366-6
DO - 10.1016/S1470-2045(15)00366-6
M3 - Article
SN - 1470-2045
VL - 17
SP - 78
EP - 89
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 1
ER -